Ratings Sensorion

Equities

ALSEN

FR0012596468

Real-time Euronext Paris Other stock markets 03:35:02 2024-04-30 am EDT			5-day change	1st Jan Change
0.71 ^EUR	0.00%		-1.66%	+65.12%

Apr. 08	Sensorion: completion of a private placement	CF
Apr. 05	Sensorion SA announced that it expects to receive ?15 million in funding	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SENSORION	+65.12%	210M	-
IQVIA HOLDINGS INC.	+1.77%	42.86B	B
LONZA GROUP AG	+46.68%	41.36B	A
MODERNA, INC.	+12.24%	42.74B	B-
CELLTRION, INC.	-8.83%	27.68B	C
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B	B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B	C+
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes